"Neuroendocrine Tumors" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Tumors whose cells possess secretory granules and originate from the neuroectoderm, i.e., the cells of the ectoblast or epiblast that program the neuroendocrine system. Common properties across most neuroendocrine tumors include ectopic hormone production (often via APUD CELLS), the presence of tumor-associated antigens, and isozyme composition.
| Descriptor ID |
D018358
|
| MeSH Number(s) |
C04.557.465.625.650 C04.557.580.625.650
|
| Concept/Terms |
Neuroendocrine Tumors- Neuroendocrine Tumors
- Neuroendocrine Tumor
- Tumor, Neuroendocrine
- Tumors, Neuroendocrine
|
Below are MeSH descriptors whose meaning is more general than "Neuroendocrine Tumors".
Below are MeSH descriptors whose meaning is more specific than "Neuroendocrine Tumors".
This graph shows the total number of publications written about "Neuroendocrine Tumors" by people in this website by year, and whether "Neuroendocrine Tumors" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1998 | 1 | 0 | 1 |
| 2000 | 1 | 0 | 1 |
| 2004 | 1 | 0 | 1 |
| 2006 | 0 | 1 | 1 |
| 2009 | 1 | 0 | 1 |
| 2011 | 1 | 0 | 1 |
| 2012 | 0 | 1 | 1 |
| 2014 | 5 | 0 | 5 |
| 2016 | 1 | 0 | 1 |
| 2017 | 3 | 0 | 3 |
| 2018 | 3 | 0 | 3 |
| 2019 | 4 | 0 | 4 |
| 2020 | 2 | 1 | 3 |
| 2021 | 2 | 0 | 2 |
| 2022 | 2 | 0 | 2 |
| 2023 | 3 | 0 | 3 |
| 2024 | 3 | 1 | 4 |
| 2025 | 4 | 0 | 4 |
| 2026 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Neuroendocrine Tumors" by people in Profiles.
-
Diagnostic yield of endoscopic ultrasound-guided fine-needle biopsy of solid pancreatic lesions with tissue sent directly in formalin for histopathologic evaluation compared with cytology: a multicenter prospective pilot study. Gastrointest Endosc. 2026 07; 104(1):107-110.
-
miR-431 Promotes Metastasis of Pancreatic Neuroendocrine Tumors by Targeting DAB2 Interacting Protein, a Ras GTPase Activating Protein Tumor Suppressor. Am J Pathol. 2020 03; 190(3):689-701.
-
Insulinoma-associated protein 1 expression in primary and metastatic neuroendocrine neoplasms of the gastrointestinal and pancreaticobiliary tracts. Histopathology. 2019 Oct; 75(4):568-577.
-
UCHL1 loss alters the cell-cycle in metastatic pancreatic neuroendocrine tumors. Endocr Relat Cancer. 2019 04 01; 26(4):411-423.
-
Neuroendocrine Tumor of the Appendix in Children. J Pediatr Hematol Oncol. 2017 03; 39(2):97-102.
-
Pretest prediction and diagnosis of metastatic lesions to the pancreas by endoscopic ultrasound-guided fine needle aspiration. J Gastroenterol Hepatol. 2015 Oct; 30(10):1552-60.
-
Octreotide long-acting repeatable among elderly patients with neuroendocrine tumors: a survival analysis of SEER-Medicare data. Cancer Epidemiol Biomarkers Prev. 2015 Nov; 24(11):1656-65.
-
Pazopanib and depot octreotide in advanced, well-differentiated neuroendocrine tumours: a multicentre, single-group, phase 2 study. Lancet Oncol. 2015 Jun; 16(6):695-703.
-
Initial treatment of well-differentiated neuroendocrine tumors. Oncology (Williston Park). 2014 Nov; 28(11):945-7.
-
Differentiation of pancreatic ductal adenocarcinoma from other neoplastic solid pancreatic lesions: a tertiary oncology center experience. Gastrointest Endosc. 2015 Feb; 81(2):370-9.